Work

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Year: 2018

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-17-b001

Authors: Monica Mita, Alain Mita, Bartosz Chmielowski, Michael Postow, Erika Hamilton, Shubham Pant, Roger Waltzman, Eric Rowinsky, Michael Szarek, Foster Gonsalves, Isabel Kurth, Celia Andreu, Ilana Pollack, Daniel Mucida, Raissa Tanqueco, Sohail Tavazoie, Masoud Tavazoie

Institutions: Cedars-Sinai Medical Center, University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, Sarah Cannon, Tennessee Oncology, The University of Texas MD Anderson Cancer Center, RGenix (United States), Rockefeller University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2787541477

Cites:

Cited by: 2

Related to: 10